Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 8/20 | 0.71 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4846223 | 1.00 | GRM2 (0.71) | GRM2DRD2DRD4DRD3 | |
| SCHEMBL4846230 | 1.00 | GRM2 (0.71) | GRM2DRD2DRD4DRD3 | |
| SCHEMBL4885674 | 0.84 | GRM2 (0.72) | GRM2DRD2DRD4 | |
| SCHEMBL4885648 | 0.84 | GRM2 (0.72) | GRM2DRD2DRD4 | |
| SCHEMBL23719405 | 0.83 | GRM2 (1.00) | GRM2DRD2DRD4 | |
| SCHEMBL23719406 | 0.72 | GRM2 (1.00) | GRM2DRD2DRD4 | |
| SCHEMBL4892780 | 0.70 | GRM2 (0.78) | GRM2DRD2DRD4DRD3 | |
| SCHEMBL4892776 | 0.70 | GRM2 (0.78) | GRM2DRD2DRD4DRD3 | |
| SCHEMBL4892766 | 0.70 | GRM2 (0.78) | GRM2DRD2DRD4DRD3 | |
| SCHEMBL23746897 | 0.70 | GRM2 (0.83) | GRM2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | GRM2 4077/4885DRD2 1974/4885DRD4 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.